COVID-19 大流行变异株时期的演变:严重急性呼吸道感染准备(SARI-PREP)研究
SARI-PREP是一项由CDC基金会资助、重症医学会Discovery项目托管的纵向多中心队列研究,纳入2020年3月至2023年4月7家美国医院住院的病毒性SARI成人患者,定义为实验室确诊呼吸道病毒感染并伴发热、咳嗽及影像学浸润或低氧血症的急性综合征。共874例患者入组,其中780例(89%)为SARS-CoV-2感染;COVID-19队列中位年龄60岁(IQR 48.0-71.0岁),66%为男性,49%属于服务不足社区,76.5%入住ICU,52.5%接受机械通气,院内死亡率为25.5%。按测序亚样本划分的四个大流行变异株时期(pre-Delta、Delta、Omicron BA.1、Omicron post-BA.1)比较,随大流行进展,ICU使用率从94%降至58%,住院时长中位数从26.0天降至8.5天,院内死亡率从32%降至12%,而合并症数量增加。作者认为,对患者层面因素的理解可能为后续变异株和未来新型病原体的治疗选择提供信息。
要点
- 874例病毒性SARI住院成人中780例(89%)为SARS-CoV-2感染,76.5%入住ICU,52.5%接受机械通气,院内死亡率25.5%。
- COVID-19队列中位年龄60岁(IQR 48.0-71.0岁),66%为男性,49%(430例)属于服务不足社区。
- 随大流行变异株时期推进,ICU使用率从94%降至58%,住院时长中位数从26.0天降至8.5天,院内死亡率从32%降至12%。
- 同一时期合并症数量增加,提示患者基础疾病负担加重但结局仍改善。
- 作者强调需要持续的临床网络以增进对已知和新型呼吸道病毒性疾病的理解。
适用人群与场景
- 纳入标准:住院且实验室确诊呼吸道病毒感染,并存在发热、咳嗽及影像学浸润或低氧血症的急性综合征的成人患者。
- 研究纳入2020年3月至2023年4月美国7家医院收治于急性 care 病房或ICU的成人患者,代表美国不同地理区域。
- 874例中780例(89%)为SARS-CoV-2感染;COVID-19队列中位年龄60岁(IQR 48.0-71.0岁),66%为男性,49%(430例)属于服务不足社区。
诊断标准与关键阈值
- SARI定义:住院且实验室确诊呼吸道病毒感染,并伴发热、咳嗽及影像学浸润或低氧血症的急性综合征。
- 大流行变异株时期基于SARS-CoV-2测序亚样本划分为:pre-Delta、Delta、Omicron BA.1、Omicron post-BA.1。
研究设计与关键结果
- 研究类型:由CDC基金会资助、重症医学会Discovery项目托管的纵向多中心队列研究,纳入7家美国医院2020年3月至2023年4月的874例病毒性SARI成人患者。
- COVID-19队列(780例):中位年龄60岁(IQR 48.0-71.0岁),66%为男性,49%(430例)属于服务不足社区。
- 76.5%入住ICU,52.5%接受机械通气,观察到的院内死亡率为25.5%。
- 随大流行变异株时期推进,ICU使用率从94%降至58%,住院时长中位数从26.0天降至8.5天,院内死亡率从32%降至12%。
- 同一时期合并症数量增加。
证据类型、等级与局限
- 证据类型:纵向多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对患者层面因素的理解可能为后续变异株和未来新型病原体的治疗选择提供信息。
- 作者强调需要持续的临床网络以改善对已知和新型呼吸道病毒性疾病的理解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has evolved through multiple phases in the United States, with significant differences in patient centered outcomes with improvements in hospital strain, medical countermeasures, and overall understanding of the disease. We describe how patient characteristics changed and care progressed over the various pandemic phases; we also emphasize the need for an ongoing clinical network to improve the understanding of known and novel respiratory viral diseases.
OBJECTIVES: To describe how patient characteristics and care evolved across the various COVID-19 pandemic periods in those hospitalized with viral severe acute respiratory infection (SARI).
DESIGN: Severe Acute Respiratory Infection-Preparedness (SARI-PREP) is a Centers for Disease Control and Prevention Foundation-funded, Society of Critical Care Medicine Discovery-housed, longitudinal multicenter cohort study of viral pneumonia. We defined SARI patients as those hospitalized with laboratory-confirmed respiratory viral infection and an acute syndrome of fever, cough, and radiographic infiltrates or hypoxemia. We collected patient-level data including demographic characteristics, comorbidities, acute physiologic measures, serum and respiratory specimens, therapeutics, and outcomes. Outcomes were described across four pandemic variant periods based on a SARS-CoV-2 sequenced subsample: pre-Delta, Delta, Omicron BA.1, and Omicron post-BA.1.
SETTING: Multicenter cohort of adult patients admitted to an acute care ward or ICU from seven hospitals representing diverse geographic regions across the United States.
PARTICIPANTS: Patients with SARI caused by infection with respiratory viruses.
MAIN OUTCOMES AND RESULTS: Eight hundred seventy-four adult patients with SARI were enrolled at seven study hospitals between March 2020 and April 2023. Most patients (780, 89%) had SARS-CoV-2 infection. Across the COVID-19 cohort, median age was 60 years (interquartile range, 48.0-71.0 yr) and 66% were male. Almost half (430, 49%) of the study population belonged to underserved communities. Most patients (76.5%) were admitted to the ICU, 52.5% received mechanical ventilation, and observed hospital mortality was 25.5%. As the pandemic progressed, we observed decreases in ICU utilization (94% to 58%), hospital length of stay (median, 26.0 to 8.5 d), and hospital mortality (32% to 12%), while the number of comorbid conditions increased.
CONCLUSIONS AND RELEVANCE: We describe increasing comorbidities but improved outcomes across pandemic variant periods, in the setting of multiple factors, including evolving care delivery, countermeasures, and viral variants. An understanding of patient-level factors may inform treatment options for subsequent variants and future novel pathogens.
参考来源
- Mukherjee V, Postelnicu R, Parker C, et al. COVID-19 Across Pandemic Variant Periods: The Severe Acute Respiratory Infection-Preparedness (SARI-PREP) Study. Crit Care Explor. 2024. PMID: 39023121. doi:10.1097/CCE.0000000000001122
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。